Related Experiment Videos
Somatostatin receptor localization of pancreatic endocrine tumors
V D Corleto1, F Scopinaro, S Angeletti
1Department of Gastroenterology, Second Medical Clinic, Policlinico Umberto I, Via del Policlinico, University La Sapienza, 00161 Rome, Italy.
Abstract:
Gastroenteropancreatic endocrine tumors are difficult to localize. At the same time the tumor is localized, though, there is an opportunity for cure or to remove tumor tissue. In this study we have prospectively examined the ability of 111In-octreotide scintigraphy, magnetic resonance imaging (MRI), and computed tomography (CT) to localize tumor lesions in 24 patients with a biochemical or histologic diagnosis of neuroendocrine tumor. In eight patients a surgical assessment of the imaging results was prospectively performed. Planar and abdominal single-photon emission tomography (SPET) images acquired 4 and 24 hours after 180 to 220 MBq of 111In-octreotide injection were evaluated and compared with conventional imaging techniques. SPET scintigraphy visualized more presumed tumor lesions (n = 39) than conventional imaging studies (MRI,n = 25; CT,n = 13); 23 of 24 patients had positive octreotide scintigraphy, 17 of 24 had positive MRI-scans, and 12 of 24 patients had positive CT scans. It was concluded that 111In-octreotide scintigraphy combined with conventional imaging improves the preoperative localization of presumably tumorous lesions in patients with gastroenterohepatic endocrine tumors.
Insights
Localizing gastroenteropancreatic endocrine tumors is challenging. 111In-octreotide scintigraphy, combined with MRI and CT, significantly improves preoperative localization of these neuroendocrine tumors.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiology
Background:
- Gastroenteropancreatic endocrine tumors present diagnostic challenges for localization.
- Accurate tumor localization is crucial for curative treatment or debulking.
- Neuroendocrine tumors require precise imaging for effective management.
Purpose of the Study:
- To prospectively evaluate the efficacy of 111In-octreotide scintigraphy compared to conventional imaging (MRI, CT) for localizing neuroendocrine tumors.
- To assess the combined utility of scintigraphy and conventional methods in preoperative tumor localization.
Main Methods:
- Prospective study involving 24 patients with diagnosed neuroendocrine tumors.
- Utilized 111In-octreotide scintigraphy (planar and SPET) at 4 and 24 hours post-injection.
- Compared scintigraphy findings with Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) results.
- Included surgical assessment in eight patients to validate imaging findings.
Main Results:
- 111In-octreotide scintigraphy visualized significantly more presumed tumor lesions (39) than MRI (25) or CT (13).
- Positive octreotide scintigraphy was observed in 23 out of 24 patients.
- MRI and CT scans were positive in 17 and 12 patients, respectively.
- Combined imaging approaches demonstrated superior lesion detection.
Conclusions:
- 111In-octreotide scintigraphy is a valuable tool for localizing gastroenteropancreatic endocrine tumors.
- Combining octreotide scintigraphy with conventional imaging (MRI, CT) enhances preoperative localization accuracy.
- Improved localization facilitates better surgical planning and patient outcomes for neuroendocrine tumors.